Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy
The Prostate · 2024
DOI: 10.1002/pros.24642 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Wei Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Andrology, Shenzhen Bao'an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China. Hauptthemen laut MEDLINE: Ferroptosis, Prostatic Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Project of Guangdong Provincial Administration of Traditional Chinese Medicine, Shenzhen Bao'an Traditional Chinese Medicine Hospital Research Program.
Abstract (Originalsprache)
Background
As the second most common cancer in men and the leading cause of cancer‐related death, prostate cancer (PCa) could potentially be treated by inducing ferroptosis. In this study, we aimed to investigate whether luteolin could induce ferroptosis in PCa cells through the transcription Factor EB (TFEB).
Methods
Different concentrations of luteolin were applied to treat normal prostate epithelial cells RWPE‐1 and PCa cell lines DU145, PC‐3, VCaP, and LNcaP. Ferrostatin‐1 (Fer‐1), Necrostain‐1 (Nec‐1), 3‐methyladenine (3‐MA), chloroquine (CQ), and the apoptosis inhibitor benzyloxycarbonyl‐Val‐Ala‐Asp(OMe)‐fluoromethylketone (Z‐VAD‐FMK) were added to treat DU145 and PC‐3 cells. Additionally, we knocked down TFEB and performed in vitro cell experiments. Finally, tumor‐forming experiments in nude mice were conducted to verify luteolin mechanism in PCa after knocking down TFEB.
Results
There was no significant difference in RWPE‐1 at 12, 24, and 48 h after treatment with 60 μM luteolin. However, a significant difference was observed between DU145 and PC‐3 cells. Luteolin exhibited a promoting effect on PCa cell death. After treatment with luteolin, cell viability, and Ki67 expression were decreased, and AnV‐PI‐positive dead cells were increased. Fer‐1, Nec‐1, 3‐MA, and Z‐VAD‐FMK reversed luteolin effects on DU145 and PC‐3 cell viability, proliferation, and AnV‐PI‐positive dead cells. Among them, Fer‐1 and 3‐MA were more effective. Luteolin‐induced increased autophagy and ferroptosis in DU145 and PC‐3 cells. Moreover, luteolin promoted ferroptosis by inducing increased autophagy in DU145 and PC‐3 cells. However, knockdown of TFEB reversed the ability of luteolin to induce lysosome degradation of ferritin. In addition, luteolin promoted PCa ferroptosis by inducing ferritinophagy in vivo.
Conclusions
Luteolin‐induced ferroptosis in PCa cells by promoting TFEB nuclear translocation and increasing ferritinophagy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Andrology, Shenzhen Bao'an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China.
- Department of Andrology, The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China.
ORCID-Profile: Wei Fu
Förderung
- National Natural Science Foundation of China
- Project of Guangdong Provincial Administration of Traditional Chinese Medicine
- Shenzhen Bao'an Traditional Chinese Medicine Hospital Research Program
Zitieren
APA
Fu, W., Xu, L., Chen, Y., Zhang, Z., Chen, S., Li, Q., & You, X. (2024). Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy. The Prostate. https://doi.org/10.1002/pros.24642
Vancouver
Fu W, Xu L, Chen Y, Zhang Z, Chen S, Li Q, et al. Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy. The Prostate. 2024. doi:10.1002/pros.24642
BibTeX
@article{Fu2024,
author = {Fu, Wei and Xu, Lei and Chen, Yingwen and Zhang, Zezheng and Chen, Shuchao and Li, Qixin and You, Xujun},
title = {Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24642}
}
EUVIMED